Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL000452

Drug Information
NameAZD1152
CompanyAstraZeneca
IndicationAcute Myeloid Leukemia, Haematological malignancies
[ICD9: 140-239, 200-209, 205, 205.0, 208.9   ICD10: C00-C96, C81-C96, C91-C95, C92, C92.0]
Phase II    
Myeloid LeukemiaPhase I/II    
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C26H31FN7O6P/c1-2-34(10-12-40-41(36,37)38)9-4-11-39-21-7-8-22-
23(16-21)28-17-29-26(22)31-24-14-20(32-33-24)15-25(35)30-19-6-3-5
-18(27)13-19/h3,5-8,13-14,16-17H,2,4,9-12,15H2,1H3,(H,30,35)(H2,3
6,37,38)(H2,28,29,31,32,33)
InChIKeyGBJVVSCPOBPEIT-UHFFFAOYSA-N
Canonical SMILESCCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCOP(=
O)(O)O    
CAS NumberCAS 722544-51-6
FormulaC26H30FN7O3
PubChem Compound IDCID 11497983.
ClinicalTrials.govNCT00497991;
NCT00952588;
TargetAurora A kinase Inhibitor[1]
Aurora A kinase Multitarget[1]
Aurora B kinaseInhibitor[1]
Aurora B kinaseMultitarget[1]
Ref 1AstraZeneca. Product Development Pipeline. January 29 2009. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543